Rare Disease Deal Benchmarks
Gene therapy, SMA, Duchenne, hemophilia, and orphan drug deal benchmarks. Benchmarks derived from 112 verified transactions.
112
Total Deals
$676M
Avg Upfront
5
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
55
license
36
acquisition
18
collaboration
2
option
1
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Hanmi Pharm → Eli Lilly and Company sonefpeglutide | license | $75M | $1.2B | Jun 2026 |
Oscotec → Agios Pharmaceuticals cevidoplenib | license | $25M | — | Jun 2026 |
Hansa Biopharma → SERB Pharmaceuticals Idefirix (imlifidase) | license | $123M | $129M | May 2026 |
BioCryst Pharmaceuticals, Inc. → Neopharmed Gentili navenibart | license | $70M | $345M | May 2026 |
Santhera → Nxera Agamree | license | $40M | $205M | Apr 2026 |
Regenxbio → Nippon Shinyaku rare disease gene therapy portfolio | license | $110M | $810M | Mar 2026 |
uniQure → CSL Hemgenix | license | $450M | $1.9B | Mar 2026 |
Amicus Therapeutics → BioMarin Pharmaceutical Amicus Therapeutics | acquisition | $4.8B | $4.8B | Dec 2025 |
Inozyme Pharma → BioMarin Pharmaceutical Inozyme Pharma | acquisition | $270M | $270M | Jul 2025 |
Regulus Therapeutics → Novartis microRNA therapeutics | acquisition | $800M | $800M | Jul 2025 |
Benchmark Your Rare Disease Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 112 verified rare disease transactions.
Run Rare Disease Benchmark